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Summary
Purpose: To study the efficacy and the safety of cladribine
(2-chlorodeoxyadenosine, 2-CDA) administered as 24-hour
infusions or as subcutaneous bolus injections at two different
doses to patients with relapsing or refractory chronic lympho-
cytic leukaemia (CLL).
Patients and methods: In this non randomised 2-cohort
study, 20 patients with pretreated CLL received cladribine at a
dose of 0.7 mg/kg/cycle as continuous i.v. infusions over seven
days (group 1) and 35 patients were treated at a reduced dose
of 0.5 mg/kg/cycle given as s.c. bolus injections for five days
(group 2). After two cycles of four week duration, response was
assessed. In the case of progressive disease, therapy was dis-
continued, otherwise a maximum of four additional cycles were
administered until best response.
Results: A total of 130 cycles were administered (group 1:
41, group 2: 89). Patient characteristics in both groups were
comparable. The median dose intensities were 0.172 mg/kg per
week and 0.123 mg/kg per week for groups 1 and 2, respec-
tively (P ^ 0.0001). The overall response rate for all 55 patients
was 38% (95% confidence interval (95% CI): 25%-52%), with
5% CR and 33% PR. Response was similar in both patient
groups (35% in group 1, 40% in group 2). No association
between cladribine dose intensity and response rate was found,
and there was no difference between patients relapsing after or
refractory to previous therapies (11 of 24 vs. 10 of 31). Median
remission duration was six months in both groups. Toxicity, in
particular infections (all WHO grades, 34% in group 1 versus
7% in group 2) and myelosuppression (grade 1-4 neutropenia,
72% versus 41% of cladribine cycles) were statistically signifi-
cantly more frequent in group 1.
Conclusion: Cladribine is active in heavily pretreated pa-
tients with chronic lymphocytic leukaemias. Dose reduction by
29% led to similar response and remission duration, but to a
significant decrease of myelotoxicity and risk of infection.
Cladribine administered as s.c. bolus injections at 0.5 mg/kg
per cycle is safe and this dose level should not be exceeded in
this patient population.
Key words: cladribine, 2-chlorodeoxyadenosine, chronic lym-
phocytic leukaemia, infection, myelotoxicity, remission dura-
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Introduction
The cornerstones of treatment in advanced chronic
lymphocytic leukaemia (CLL) are alkylators, in partic-
ular chlorambucil and cyclophosphamide, with or with-
out the addition of corticosteroids. In the early 1980s
purine analogs were introduced into clinical research
and showed striking activity in relapsing as well as
refractory CLL. Both fludarabine phosphate [1] and
cladribine (2-chlorodeoxyadenosine) [2] show response
rates varying between 30% to 70% depending on the
patient selection [3-9]. Data on remission durations are
scarce; in four studies [6-9] it varies between four to 20
months.
Cladribine was first reported to be active in CLL by
Piro et al. in 1988 [7]. Patients received a cladribine dose
of 0.7 mg/kg/cycle as continuous i.v. infusions over
seven days. At present, data are available on more than
300 previously treated patients as well as about 100
previously untreated patients who received cladribine
either at 0.1 mg/kg/day by continuous infusions for
seven consecutive days or by two-hour infusions usually
at a dose of 0.14 mg/kg/day for five consecutive days [6-
15]. Despite the high rate of responses, the routine use of
cladribine was dampered by its marked side effects, in
particular infections and myelosuppression [2,16,17]. In
addition, the rather complicated way of its administra-
tion (daily infusions) renders this therapy rather cumber-
some especially in elderly patients. To find a simpler way
of cladribine administration, we tested the subcutaneous
route of cladribine administration which is associated
with a different plasma cladribine concentration-time
profile and the mean residence time when compared
with continuous intravenous administration [18].
In this two-cohort study we compared the activity
and toxicity of cladribine administered intravenously as
24-hour infusions over seven days versus subcutaneous
bolus injections over five days. In the attempt to decrease
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the side effects, the dose intensity of cladribine was re-
duced by 29% in patients receiving the subcutaneous
schedule.
Patients and methods
Study design
This study includes two consecutive prospective mullicentre phase II
trials in Switzerland: first trial from June 1992 to May 1993 (group I),
second trial from June 1993 to October 1995 (group 2). Due to a high
incidence of infections seen in group 1. the cladribine dose was reduced
by 29% in group 2. The protocols were approved by the local ethic's
committee of each participating centre. The study was performed in
keeping with good clinical practice regulations and informed consent
was given by all patients.
Eligibility criteria
Patients were required to have CLL of B-cell type of International
stage B or C Immunophaenotyping was performed to confirm the
diagnosis. Patients were required to have undergone prior conven-
tional treatment, including at least one alkylating agent and either
failed to respond or developed progressive disease after an initial
response. Patients had to be free of prior therapy for four or more
weeks. All patients were older than 18 years. No upper age limit was
specified. However, a performance status of ^ 2 and a life expectancy
of > 3 months were required as well as absence of active infection, and
adequate cardiac, renal and hepatic function. Exclusion criteria were
prior malignancy (other than non-melanomatous skin cancer or ad-
equately treated stage I in situ cervical cancer), or peripheral blood
cytopenia (leucocyte count < 3.0 x lO'/l, neutrophil count < 1.0 x io'/l
or thrombocyte count < 100 x lO'/l) unless this was clearly related to
bone marrow infiltration by CLL.
Pretreatment investigations
The diagnosis of CLL was confirmed before start of treatment. The
extent of disease was determined by standardised staging evaluation,
which included CT scanning of the chest, abdomen and pelvis, and
bone marrow aspiration and trephine biopsy. Kidney function and
liver enzymes were measured.
Drug therapy
Patients were treated with cladribine (provided by Dr. Z. Kazimierczuk
et al. [19] and by Lipomed, Basel, Switzerland) at a daily dose of O.I
mg/kg/day diluted in 0.9% saline solution. In group I, cladribine was
given as continuous i.v. infusions over seven days. In group 2, the drug
was self-administered by the majority of patients as s.c. bolus injec-
tions over five days mostly on an outpatient basis. Cladribine cycles
were repeated at > 4 week intervals. After two cycles staging was
performed, and therapy was discontinued in case of progressive dis-
ease. In responders, therapy was continued at physician's request until
best response, but for a maximum of six cycles. If patients received one
2-CDA course only, due to toxicity or further treatment refusal by the
patient, response was assessed four weeks after 2-CDA start. Weekly
blood cell counts including granulocytes were performed. Treatment
was delayed if the neutrophil count was less than 1.0 x 109/l and/or the
platelet count was less than 100 x IO9/I, unless the cause was clearly
due to infiltration of the bone marrow by CLL. No routine antimicro-
bial prophylaxis was given, and no concomitant therapy such as antie-
metics or steroids were administered.
Response criteria
All responses were reviewed by two of us (DCB, DR) using the
response criteria recommended by the National Cancer Institute-
sponsored Working Group [20]. Peripheral lymph node enlargements
were documented after each cladribine cycle. Sites of disease not
assessable by clinical examination (mediastinal and retroperitoneal
lymphadenopathy, bone marrow infiltration) were examined by chest
X-ray, CTscan and/or bone marrow examination after two cycles as
well as at completion of cladribine therapy. Duration of remission was
assessed through clinical and radiological (where appropriate) exami-
nations as well as blood cell counts at three month intervals until
relapse.
Toxicity criteria
Toxicity was evaluated according to World Health Organisation (WHO)
criteria [21]. Physical examination and full blood count including
differential were done weekly.
Statistical analyses
All patients were evaluated for toxicity, response, time to treatment
failure and response duration. Time to treatment failure was calculated
from date of enrollment to either disease progression/relapse, discon-
tinuation of treatment for toxicity or death due to CLL, whichever
occurred first. Remission duration was calculated from the date of
response until relapse, progression or death due to CLL. Survival
curves were compared using the log-rank test. Contingency tables
were analysed by Fisher's*exact test, while continuous variables were
analysed by the Wilcoxon rank sums test. Due to relatively small
sample size, all /"-values should be interpreted with caution; e.g., the
statistical power is low and significant trends may be missed.
Results
Study population
We report on 55 patients with previously treated CLL
who were treated with cladribine therapy between June
1992 and October 1995 in two cohorts. Twenty patients
received infusional cladribine (group 1: 0.7 mg/kg/cycle
as continuous i.v. infusions over seven days). A further
35 patients were administered cladribine subcutaneously
as bolus injections (group 2: 0.5 mg/kg/cycle over five
days). The median age was 68 years, ranging from 43 to
79 years. Two patients had International stage B disease,
and 53 patients had stage C. Patient characteristics are
shown in Table 1. All patients are evaluable for toxicity
and response. Both patient groups are well balanced
with respect to CLL prognostic factors (gender, age,
performance status, lymphocyte count and disease sta-
tus; refractory to or relapsing after standard therapy).
The number of different pretreatments (group 1 vs.
group 2: median 3 vs. 2, P = 0.04) appeared to be greater
in group 1.
Therapy
Overall, 130 cycles of cladribine were administered. The
median number of cycles was 2 (range 1-5, in group 1;
and 1-6 in group 2) in both groups. Responders of group
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Table 1. Patient characteristics and cladribine therapy.
Group 1 Group 2 /"-value
Number of patients
Gender
Male
Female
Age (in years)
Median
Range
Years since diagnosis
Median
Range
Stage of disease
(international stage)
A
B
C
Performance status
0
1
2
3
Number of pretreatments
Median
Range
Stalus after pretreatment
In relapse
Refractory
Blood values at study
entry
Hb(g/1)
Median
Range
Lymphocytes (x 109/l)
Median
Range
Platelets (xlO9/l)
Median
Range
Number of cladribine
cycles
Median
Range
Total of cladribine cycles
Number of patients with
> 3 cycles
Total dose per patient
(mg/kg)
Median
Range
Dose intensity (accord-
ing to study design, in
mg/kg/wk)
Median
Range
20 (36%)
15(75%)
5 (25%)
70.
52-76
4.7
0.2-11.3
0
2
18
8
10
1
1
3
1-7
9
11
107
57-114
46
0.9-32
115
10-279
2
1-5
41
5 (of 20)
1.4
0.7-3.5
0.172
0.085-0.179
35 (64%)
24 (69%)
11(31%)
66
43-79
3.2
0.03-21.9
0
0
35
13
16
4
2
2
1-5
15
20
112
70-166
' 39
0.5-754
108
7-362
2
1-6
89
17 (of 35)
1.0
0.5-3.0
0.123
0.054-0.127
0.61
0.06
0.18
0.13
0.93
0.04
1.00
0.57
0.29
0.55
0.10
0.15
0.96
< 0.0001
1 and 2 received two (median, range one to four) and
three (one to six) cladribine cycles, respectively. Twenty-
two patients received > 3 cycles (group 1, n = 5 of 20;
group 2, n = 17 of 35; P = 0.15). The total cladribine dose
administered in both groups was similar (median: 1.4
versus 1.0 mg/kg, P = 0.96). The median dose-intensity
for patients in group 1 with higher dose 2-CDA was
0.172 mg/kg/week (range 0.085-0.179 mg/kg/week). As
expected from the study design, the dose intensity was
Table 2. Response rate, remission duration and time to treatment
failure.
a) Response rate, remission duration and time to treatment failure
according to cladribine dose and route of administration
Group 1 Group 2 /"-value
Response rate (CR + PR)
95% confidence interval
Response
CR
PR
NC
PD
Remission duration (months)
Time to treatment failure
(months)
35% 40%
15%-59% 24%-58%
0.78
1
6
10
3
6
4.5
2
12
17
4
6
3.8
0.88
0.74
b) response rate according to blood values at start of therapy
CR + PR NC + PD />-value
Hb (g/1)
Median
Range
Lymphocytes (x 10'/l)
Median
Range
Platelets (x 109/l)
Median
Range
123
57-166
41
1-174
168
16 353
105
70-163
39
1.5-152
83
7-362
0.04
0.23
0.004
Abbreviations: CR - complete remission; PR - partial remission;
NC - no change; PD - progressive disease.
reduced by 29% in group 2 (0.123, 0.054-0.127, P <
0.0001, Table 1). In 15 patients (group 1/2 = 8/7) cladri-
bine therapy was discontinued because of CLL progres-
sion (n = 4), infections (n = 4), autoimmune-haemolytic
anaemia (n = 1), and patient refusal (n = 6) before
administration of the second cycle.
Response to therapy
The overall response rate of the 55 patients was 38%
(95% confidence interval (95% CI): 25%-52%), with a
CR rate of 5% (95% CI: 1%-15%) and a PR rate of 33%
(95%. CI: 21%-47%) (Table 2a). Stable disease was
obtained in further 16 patients (29%) who were progress-
ing under previous therapy. There was no difference in
the response rates between the two study groups (re-
sponse in group 1 and 2: 35% vs. 40%) and no associa-
tion between cladribine dose intensity and response rate
was found. In a univariate analysis, separately per-
formed in each group, the response rate did not depend
on prognostic factors such as age, gender, duration of
disease, lymphocyte count at study entry, and number of
different pretreatments. More importantly, in .both
study groups the response rates were independent of
whether patients relapsed after or were refractory to
previous chemotherapy (46% versus 32%). Response,
however, was associated with a higher platelet and
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haemoglobin count before cladribine initiation (P ^
0.04, Table 2b).
Tumour load reduction of >50% as assessed by
lymph node, liver and spleen measurements as well as
lymphocyte count decrease of > 50% was seen in 23
patients in which the response criteria according to the
blood counts did not reach the strict criteria for re-
sponse. In three patients, no tumour was detectable
(including bone marrow biopsy and CT scans), haemo-
globin and platelet count however did not completely
recover. This observation was independent of patient
groups (group 1:10 of 20, group 2: 13 of 35).
Follow-up
After the last cladribine cycle, the patients were ob-
served without receiving further therapy until relapse or
progression. The median time to treatment failure was
4.5 months and 3.8 months in group 1 and 2, respectively
(Figure la). Median follow-up time was 19.3 months,
while median overall remission duration was six months
in both groups (Figure lb).
Toxicity
Non-haematologic toxicity was mild. Overall, three of
20 patients (15%) in group 1 had no side effects com-
pared with 16 of 35 patients (46%) in group 2 (P = 0.04).
Nausea (grade 2) was seen in one patient, but vomiting
did not occur. No patient had mucositis, alopecia, and
pulmonary, cardiac or renal toxicities. Moderate skin
exanthema and induration were occasionally seen at the
injection sites in group 2. Three patients of group 1
developed moderate phlebitis. Treatment was discontin-
ued in nine patients due to toxicity, in eight patients
because of severe infections (group 1: seven patients,
group 2: one patient), and in one patient due to auto-
immune-haemolytic anaemia (group 2) acquired during
treatment.
Myelotoxicity and immunosuppression with oppor-
tunistic infections were the most important side effects.
Twenty-six of 36 cycles (72%) of cladribine administered
to patients in group 1 were associated with grade 1-4
neutropenia. With dose reduction in group 2 this high
incidence was reduced to 28 of 68 cycles (41%). Decrease
of platelets < 100 x 109/l was seen in 18 of 37 cycles in
group 1 (49%) and in 29 of 79 cycles in group 2 (37%).
One patient in group 2 developed an immune haemo-
lytic anaemia after the first cycle which was successfully
treated with steroids.
Infectious complications were the most important
adverse event in group 1. Infections occurred in 14 out
of 41 cycles (34%) given to 10 of 20 patients (50%). The
incidence was much lower in group 2: seven of 89 cycles
administered were complicated by infections (8%), and
seven of 35 patients (20%) suffered from infection (P =
0.03, by patient). This was also true for infections of
grade >2 (10 of 41 vs. two of 89 by cycle, and nine of
20 vs. two of 35 by patient, P = 0.0009). All infections
occurred within 40 days after the start of any cladribine
cycle. The infectious agents are listed in Table 3. In a
univariate analysis, infections of grade ^ 2 (both groups
together) were independent of age, performance status,
disease duration, number of pretreatments, and lympho-
cyte count as well as status of disease. Neutrophil count
before start of therapy was associated with infection
risk (P = 0.008).
Discussion
Cladribine at a dose of 0.6-0.7 mg/kg/cycle has been
given intravenously to more than 400 patients with CLL
leading to responses varying between 20% to 70% [6-
15]. As in the present study, a large number of these
patients were heavily pretreated, refractory to previous
therapy and/or progressive. Our response rate of 38% is
in the range of other studies using the same response
criteria [24]. It is of interest that a > 50% tumour load
reduction as assessed by measurements of lymph node/
liver/spleen enlargements and lymphocyte count was ob-
served in another 35% of patients. However, the blood
cell counts (in particular platelets) did not reach normal
values, and thus, these patients did not fulfil the Interna-
tional Criteria for response [24]. It is, however, possible
that long-lasting myelotoxicity after several cytostatic
therapies including cladribine was the cause for this
persistent cytopenia. Indeed, we have recently reported
persistent thrombocytopenia in previously untreated fol-
725
Table 3. Type of infections.
Skin infections
Herpes simplex (labialis,
genitalis)
Herpes zoster
Abscess of unknown origin
Fungal infections
Bronchopneumonia
Septicaemia
Proteus vulgaris
Staph. aureus
Miscellaneous
Cholecystitis acuta
Sinusitis/otitis media
Flu
Total
Total cycles with infections
Percentage of cycles with
infections
Group I
WHO grade
All
1
1
1
1
6
-
1
1
1
1
14
1 2
1 -
- -
- 1
1 -
2 -
- -
- -
- -
- 1
- 1
4 3
14/4:
34%
3
-
-
-
-
3
-
1
1
-
-
5
1
4
-
1
-
-
1"
-
-
-
-
-
2
Group 2
WHO grade
All
1
-
1
1
-
1
-
-
2
1
7
1 1 2
1 -
- -
- -
1 -
- -
- -
- -
- _
2 -
1 -
5 -
7/89
8%
3 4
- -
- -
1 -
- -
- -
1 -
- -
- -
- -
2 -
' Lethal.
occurrence of infections and myelotoxicity in group 2.
This is perhaps one of the explanations of why the
frequency of grade 1 infections (in particular Herpes
simplex) were similar in both groups. Our results there-
fore indicate strongly that the diminution of infection
risk in group 2 is real and due to the reduced cladribine
dose intensity.
There remains the question as to which purine nucleo-
side should be used for CLL, since both fludarabine and
cladribine are highly active in this disease [3]. A rando-
mised study comparing response rate, durability of re-
sponse, and toxicity profile after fludarabine, chloram-
bucil or cladribine therapy has been recently started by
G. Juliusson et al. in previously untreated CLL patients.
In conclusion our study shows that cladribine is an
effective salvage therapy in CLL and that cladribine can
be administered safely as s.c. bolus injections on an
outpatient basis. A 29% reduction from standard dose
resulted in a significant decrease in infection rate togeth-
er with a comparable response rate. Further trials with
relatively larger sample sizes should confirm these find-
ings in order to establish the optimum dose for cladri-
bine in patients with CLL.
licular lymphomas after cladribine [16]. Taken together,
cladribine is highly active in pretreated CLL, with a
total response of 67% when refractory and progressive
patients, who reached clinical stabilisation under cladri-
bine, are also included. The remission duration and time
to treatment failure, similar in both' groups, are in agree-
ment with reported data of four to 20 months [6-9].
The high response rate together with durable remis-
sions (median of six months in our study) makes cladri-
bine a suitable drug for refractory or relapsing CLL
patients. However, toxicity (myelotoxicity and infec-
tions, mainly of opportunistic type [12, 22-24]) and its
rather complicated-way of administration are reasons to
withhold the drug. We therefore aimed to simplify cla-
dribine administration and to decrease the side effects
by dose reduction. Our results show that i.v. infusions
(over 24 hours) give no advantage and that subcutane-
ous cladribine bolus injections are feasible on an out-
patient basis. Indeed, most patients were able to inject
the daily dose themselves and were seen in the oncology
departments only once every four weeks. Furthermore,
the dose reduction by 29% led to a clear decrease in the
incidence of side effects, in particular less neutropenias
and perhaps more importantly, to a diminished risk of
infections (P = 0.03), especially of severe grades ( ^2 ,
P = 0.0009). Conversely, the response rate was appa-
rently not influenced by the dose reduction [P = 0.78).
The present study is not a randomised trial. However,
all participating physicians were informed about the
increased risk of infections in group 1 before the dose
was reduced. At this time it was decided by the partic-
ipating physicians not to administer a prophylactic anti-
microbial therapy, but to reduce the dose. Special atten-
tion was therefore directed by the physicians to the
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